Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-01-08
2008-01-08
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230
Reexamination Certificate
active
07316907
ABSTRACT:
Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.
REFERENCES:
patent: 4578770 (1986-03-01), Mitani
patent: 4596792 (1986-06-01), Vyas
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4601903 (1986-07-01), Frasch
patent: 4608251 (1986-08-01), Mia
patent: 2003/0211624 (2003-11-01), Goldknopf et al.
Yang et al (Molec. Parmacol., 2002, 61:269-276).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Lewin, B. (Genes VI, Oxford University Press, Inc., NY, Chapter 29, 1997).
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
Mallampalli et al. (Biochem. J. vol. 318, 1996, pp. 333-341).
Dermer (Bio/Technology, 1994, 12:320).
Aitken et al., “14-3-3 proteins in cell regulation,” 30(4):351-360, 2002.
Aitken et al., “14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins,”Trends Biochem Sci, 17:498-501, 1992.
Aitken et al., “Kinase and neurotransmitters,”Nature, 344(6267):594, 1990.
Aitken, “14-3-3 and its possible role in coordinating multiple signaling pathways,”Trends Cell Biol, 6(9):341-347, 1996.
Albertson, “Profiling breast cancer by array CGH,”Breast Cancer Research and Treatment, 78:289-298, 2003.
Ali et al., “Amplification of c-erbB-2 and aggressive human breast tumors?”Science, 240:1795-1798, 1988.
Bonnefoy-Berard et al., “Association of phosphatidylinositol 3-kinase (PI3-K) with 14-3-3 proteins,” abstract #4069,The 9thInternational Congress of Immunology, San Francisco, CA, Jul. 23-29, 1995.
Bonnefoy-Bernard, “Inhibition of phosphatidylinositol 3-kinase activity by associateion with 14-3-3 proteins in T cells,”Proc. Natl. Acad. Sci., USA, 92:10142-10146, 1995.
Brunet et al., “Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor,”Cell, 96(6):857-868, 1999.
Cantley, “The phosphoinositide 3-kinase pathway,”Science, 296:1655-1657, 2002.
Chan et al., “Modulation of the Ca2+-activated CI−channel by 14-3-3ε,”Biochem Biophys Res Commun, 270(2):581-587, 2000.
De Valck et al., “A20 inhibits NF-κB activation independently of binding to 14-3-3 proteins,”Biochem Biophys Res Commun, 238(2):590-594, 1997.
Ferguson et al., “High frequency of hypermethylation at the 14-3-3 δ locus leads to gene silencing in breast cancer,”Proc. Natl. Acad. Sci., USA, 97(11):6049-6054, 2000.
Fodor et al., “A pancreatic exocrine cell factor and AP4 binding overlapping sites in the amylase 2A enhancer,”Biochemistry, 30(33):8102-8108, 1991.
Fry et al., “A specific inhibitor of the epidermal growth factor receptor tyrosine kinase,”Science, 265(5175):1093-1095, 1994.
Guthridge et al., “Site-specific serine phosphorylation of the IL-3 receptor is required for hemopoietic cell survival,”Mol Cell, 6(1):99-108, 2000.
Hacia et al., “Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis,”Nature Genet, 14:441-449, 1996.
Hermeking et al., “14-3-3σ is a p53-regulated inhibitor of G2/M progression,”Mol Cell, 1(1):3-11, 1997.
Ichimura et al., “Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases,”Proc. Natl. Acad. Sci., USA, 85(19):7084-7088, 1988.
Ichimura et al., “Widespread distribution of the 14-3-3 protein in vertebrate brains and bovine tissues: correlation with the distributions of calcium-dependent protein kinases,”J. Neurochem, 56(4):1449-1451, 1991.
Isobe et al., “Distinct forms of the protein kinase-dependent activator of tyrosine tryptophane hydroxylases,”J. Mol Biol, 217(1):125-132, 1991.
Kallioniemi et al., “Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors,”Science, 258(5083):818-821, 1992.
Laronga et al., “Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression,”J. Biol. Chem., 275(30):23106-23112, 2000.
Liu et al., “Activation-modulated association of 14-3-3 proteins with Cbl in T cells,”J. Biol. Chem., 271(24):14591-14595, 1996.
Liu et al., “Crystal structure of the zeta isoform of the 14-3-3 protein,”Nature, 376(6536:191-194, 1995.
Masters and Fu, “14-3-3 proteins mediate and essential anti-apoptotic signal,”J. Biol. Chem., 276(48):45193-45200, 2001.
Moore and Perez, “Specific acidic proteins of the nervous system,” In:Physiological and biochemical aspects of nervous integration, Carlson (Ed.,) 343-359, Prentice-Hall, NJ, 1967.
Munday et al., “Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3,”Blood, 96(2):577-584, 2000.
Munday et al., “The phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein IB-IX-V complex and 14-3-3 zeta,”Cell Biology International, 24(12):981, 2000.
Pease et al., “Light-generated oligonucleotide arrays for rapid DNA sequence analysis,”Proc. Natl. Acad. Sci. USA, 91:5022-5026, 1994.
Rittinger et al., “Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding,”Mol. Cell, 4:153-166, 1999.
Rogers et al., “Molecular prognostic indicators in breast cancer,”Eur. J. Surg. Oncol., 28(5):467-478, 2002.
Rosenquist et al., “Evolution of the 14-3-3 protein family: does the large number of isoforms in multicellular organisms reflect functional specificity,”J. Mol. Evol., 51(5):446-458, 2000.
Shin et al., “Multiple isoforms of the regulatory subunit for phosphatidylinositol 3-kinase (P3-kinase) are expressed in neurons in the rat brain,”Biochem. Biophys. Res. Commun., 246(2):313-319, 1998.
Shoemaker et al., “Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy,”Nature Genet., 14:450-456, 1996.
Sladeczek et al., “The Cdk-like protein PCTAIRE-1 from mouse brain associates with p11 and 14-3-3 proteins,”Mol Gen Genet, 254:571-577, 1997.
Slamon et al., “Studies of the HER-2
eu proto-oncogene in human breast and ovarian cancer,”Science, 244:707-712, 1989.
Toker et al., “Protein kinase C inhibitor proteins: purification from sheep brain and sequence similarity to lipocortins and 14-3-3 protein,”Eur. J. Biochem., 191(2):421-429, 1990.
Veltman et al., “Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors,”Cancer Res., 63:2872-2880, 2003.
Vercoutter-Edouart et al., “Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells,”Cancer Res., 61(1):76-80, 2001.
Vivanco and Sawyers, “The phosphatidylinositol 3-kinase-AKT pathway in human
Hung Mien-Chie
Li Ping
Neal Christopher L.
Nguyen Nina T.
Pollock Raphael E.
Aeder Sean E
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Yu Misook
LandOfFree
14-3-3 zeta over-expression as a poor prognosis factor, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 14-3-3 zeta over-expression as a poor prognosis factor, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 14-3-3 zeta over-expression as a poor prognosis factor, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2798943